Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1318524,
author = {Kolek, Vitezslav and Grygarkova, Ivona and Koubkova, Leona and Skřičková, Jana and Ostrizkova, Lenka and Svecova, Jirina and Sixtova, Dimka},
booktitle = {16th World Conference on Lung Cancer},
keywords = {non small cell lung cancer; adjuvant chemotherapy; vinorelbine; carboplatin},
language = {eng},
title = {Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell- Lung Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study},
year = {2015}
}
TY - CONF
ID - 1318524
AU - Kolek, Vitezslav - Grygarkova, Ivona - Koubkova, Leona - Skřičková, Jana - Ostrizkova, Lenka - Svecova, Jirina - Sixtova, Dimka
PY - 2015
TI - Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell- Lung Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study
KW - non small cell lung cancer
KW - adjuvant chemotherapy
KW - vinorelbine
KW - carboplatin
N2 - Background: Adjuvant cisplatinum-based chemotherapy is recommended in patients with stages IB (> 4 cm), IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Vinorelbine with cisplatin are preferable drugs in this indication, but the side effects of this treatment were not negligible in big adjuvant trials. Carboplatin with vinorelbine given intravenously switched to orally were applied in a multicentre prospective study SWITCH I to give better comfort, higher tolerability and comparable effectivenes as standard adjuvant chemotherapy. The recruitment period started in January 12th, 2005 and lasted till September 5th, 2008. Conclusion: Adjuvant chemotherapy with carboplatinum and vinorelbine given intravenously on the day 1 and orally on the day 8 in 21 day regimen appears to be a comfortable and tolerable therapy in radically resected NSCLC. It provides higher dose intensity and more of acomplished treatments compared to big adjuvant trials and LACE meta-analysis, in which these parametres varied between 50 % to 76 % only. Survival results are comparable to LACE (3-year survival 70,3% vs 64.3%), 5-year survival 56,2% vs 55.1%) and MOS 5.9 vs 5.15 y).
ER -
KOLEK, Vitezslav, Ivona GRYGARKOVA, Leona KOUBKOVA, Jana SKŘIČKOVÁ, Lenka OSTRIZKOVA, Jirina SVECOVA a Dimka SIXTOVA. Adjuvant Chemotherapy in Patients with Resected Non-Small-Cell- Lung Cancer Treated with Carboplatin and Oral Vinorelbine - SWITCH I Study. In \textit{16th World Conference on Lung Cancer}. 2015. ISSN~1556-0864.
|
